Farxiga vs Tresiba Cost and Access Head-to-Head

What Are Farxiga and Tresiba, and How Do They Differ?

Farxiga and Tresiba work through entirely different biological mechanisms. Dapagliflozin blocks the SGLT2 transporter in the renal proximal tubule, forcing the kidneys to excrete roughly 70 g of glucose per day regardless of insulin levels. Insulin degludec is a basal insulin that directly replaces or supplements endogenous insulin secretion, binding insulin receptors to suppress hepatic glucose output and promote peripheral glucose uptake.

Mechanism of Action

Dapagliflozin's glucose-lowering is insulin-independent. This matters clinically because it produces a low intrinsic risk of hypoglycemia as monotherapy, and it adds a meaningful glucose-lowering effect even in patients with significantly impaired beta-cell function [1]. The FDA approved dapagliflozin for type 2 diabetes in January 2014, followed by approvals for heart failure with reduced ejection fraction (HFrEF) in 2020, heart failure with preserved ejection fraction (HFpEF) in 2022, and chronic kidney disease (CKD) in 2021 [2].

Insulin degludec forms multi-hexamer chains at the injection site, releasing monomers slowly over more than 42 hours. This ultra-long half-life produces a flat pharmacokinetic profile with a coefficient of variation roughly half that of insulin glargine U-100, meaning day-to-day glucose control is more consistent [3]. The FDA approved insulin degludec (Tresiba) in September 2015 [4].

Which Patients Typically Use Each Drug

Tresiba is appropriate for any patient who requires basal insulin replacement, all type 1 diabetes patients, and type 2 patients whose oral or non-insulin injectable regimens no longer achieve adequate glycemic control. Farxiga is indicated earlier in the type 2 diabetes continuum and now carries guideline-directed indications independent of glycemic status: the 2023 American Diabetes Association Standards of Care recommend an SGLT2 inhibitor for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD with albuminuria regardless of HbA1c [5].

Efficacy: Head-to-Head Glycemic Data

No published randomized controlled trial has directly compared dapagliflozin with insulin degludec in a head-to-head design. The evidence base is parallel, not intersecting, so clinical comparisons rely on individual trial data and network meta-analyses.

Farxiga Glycemic Outcomes

Across the phase 3 DECLARE-TIMI 58 trial (N=17,160), dapagliflozin 10 mg reduced HbA1c by approximately 0.4% versus placebo after 4 years of follow-up in a population with a mean baseline HbA1c of 8.3% [6]. The reduction was modest relative to insulin, reflecting that the trial enrolled patients already on multiple background therapies. In patients naïve to glucose-lowering therapy, dapagliflozin 10 mg produced HbA1c reductions of 0.84% to 0.96% versus placebo at 24 weeks in pooled phase 3 analyses [7].

Tresiba Glycemic Outcomes

In the DEVOTE trial (N=7,637), insulin degludec achieved a mean HbA1c of 7.5% at week 52 versus 7.6% with insulin glargine U-100, confirming non-inferiority (P<0.001 for non-inferiority) [8]. More clinically relevant was the hypoglycemia finding: insulin degludec produced 27% fewer confirmed hypoglycemic episodes (rate ratio 0.73, 95% CI 0.70-0.77, P<0.001) and 36% fewer nocturnal hypoglycemic episodes (rate ratio 0.64, 95% CI 0.60-0.68, P<0.001) compared with glargine U-100 [8].

What Network Meta-Analyses Show

A 2021 Cochrane-registered network meta-analysis of glucose-lowering agents in type 2 diabetes found that SGLT2 inhibitors and basal insulins occupy different rungs on the treatment escalation ladder, with basal insulin producing larger absolute HbA1c reductions (1.5% to 2.5% from high baselines) but substantially higher rates of hypoglycemia [9]. These drugs are additive when combined. Combining dapagliflozin with basal insulin in the DUAL trials framework reduced hypoglycemia risk versus up-titrated insulin alone [10].

Cardiovascular and Renal Outcomes

This is where Farxiga's evidence base expands well beyond what any basal insulin currently offers. Tresiba demonstrated cardiovascular safety; Farxiga demonstrated cardiovascular and renal benefit.

DAPA-HF: Farxiga in Heart Failure

In DAPA-HF (N=4,744), dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo (hazard ratio 0.74, 95% CI 0.65-0.85, P<0.001) in patients with HFrEF [11]. The benefit was present regardless of whether patients had type 2 diabetes, establishing dapagliflozin as a foundational heart failure therapy independent of glucose management. This trial directly informed FDA approval for HFrEF in May 2020 [2].

The DELIVER trial (N=6,263) extended this benefit to HFpEF, where dapagliflozin reduced the primary composite endpoint by 18% (hazard ratio 0.82, 95% CI 0.73-0.92, P<0.001) [12].

DEVOTE: Tresiba Cardiovascular Safety

The DEVOTE trial was designed as a cardiovascular outcomes trial to satisfy FDA requirements. Insulin degludec was non-inferior to insulin glargine U-100 on the primary MACE endpoint (hazard ratio 0.91, 95% CI 0.78-1.06, P<0.001 for non-inferiority) [8]. Tresiba did not demonstrate cardiovascular superiority, but it confirmed that using it instead of glargine does not add cardiac risk.

DAPA-CKD: Farxiga in Chronic Kidney Disease

In DAPA-CKD (N=4,304), dapagliflozin reduced the risk of sustained decline in eGFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes by 39% versus placebo (hazard ratio 0.61, 95% CI 0.51-0.72, P<0.001) [13]. The trial was stopped early due to overwhelming efficacy. Patients with type 1 diabetes were excluded from this approval. No comparable renal outcomes trial exists for insulin degludec.

Safety Profiles

Farxiga Safety Signals

The most serious risk with dapagliflozin is diabetic ketoacidosis (DKA). Rates in clinical trials are low, approximately 0.1% per year in type 2 diabetes populations, but DKA can occur at near-normal glucose levels (euglycemic DKA), making diagnosis harder [14]. The FDA added a boxed warning for this risk in 2015 [2]. Genital mycotic infections occur in roughly 6% to 8% of patients. Urinary tract infections are modestly increased. Volume depletion and hypotension may occur, particularly in elderly patients or those on loop diuretics [14].

Dapagliflozin is contraindicated in patients with eGFR <25 mL/min/1.73m² for glycemic indications, though the CKD indication extends use to lower eGFR ranges under close monitoring [2].

Tresiba Safety Signals

Hypoglycemia is the primary risk. Severe hypoglycemia requiring assistance occurred at a rate of 0.83 events per patient-year in the type 1 diabetes arm of the BEGIN Basal-Bolus Type 1 trial [15]. Weight gain of 2 to 4 kg is typical with insulin initiation. Injection site reactions occur in a small percentage of patients. Insulin degludec carries no boxed warning beyond the standard insulin hypoglycemia warning common to all insulin products [4].

Cost: What Patients Actually Pay

Both drugs carry high US list prices, but the actual out-of-pocket cost depends on insurance tier placement, manufacturer savings programs, and whether a biosimilar or generic alternative is available.

Farxiga List Price and Savings Programs

The US list price for Farxiga 10 mg (30 tablets) is approximately $550 to $600 per month as of early 2025. AstraZeneca offers the Farxiga Savings Card, which may reduce the cost to $0 to $10 per month for commercially insured patients who meet eligibility criteria. Patients without insurance can access the AZ&ME prescription savings program if their household income falls below 400% of the federal poverty level [16]. No FDA-approved generic dapagliflozin exists as of early 2025. The earliest plausible generic entry, based on patent expiry estimates, is 2025 to 2027, though patent litigation may delay this.

Tresiba List Price and Biosimilar Field

Insulin degludec U-100 (5 FlexTouch pens, 3 mL each) carries a US list price of approximately $350 to $450 per month. Novo Nordisk offers the My$99Insulin program, which provides a 30-day supply of any Novo Nordisk insulin, including Tresiba, for $99 per month for uninsured or underinsured patients who apply directly [17]. No FDA-approved biosimilar of insulin degludec has launched in the US market as of early 2025, though biosimilar applications are under review. Insulin glargine biosimilars (Semglee, Rezvoglar) offer a lower-cost basal insulin alternative for patients who can use glargine instead.

Insurance Tier Placement

On most commercial formularies, both drugs occupy Tier 3 or Tier 4, generating copays of $60 to $150 per month after deductible. Formulary placement shifts yearly. Some Medicare Part D plans place dapagliflozin on Tier 3 with a preferred cost-share under the Inflation Reduction Act insulin cap, which capped insulin copays at $35 per month for Medicare enrollees starting January 2023 [18]. The $35 Medicare cap applies to insulin products including Tresiba but does not apply to dapagliflozin, which is not an insulin.

Access: Prior Authorization and Step Therapy

Prior Authorization Requirements

Both drugs face prior authorization (PA) requirements on many commercial and government plans. For Farxiga, PA criteria often require documented type 2 diabetes diagnosis, HbA1c above a threshold (commonly 7.5% to 8.0%), and a trial of metformin unless contraindicated. Heart failure and CKD indications may carry separate PA pathways that bypass the glycemic criteria [19].

Tresiba faces PA requirements that typically require prior trial of a formulary-preferred basal insulin, usually insulin glargine (Basaglar or Semglee) or insulin detemir. Prescribers must document clinical justification for Tresiba specifically, most commonly the 36% nocturnal hypoglycemia reduction from DEVOTE, to support medical necessity [8].

Step Therapy Barriers

Step therapy policies require patients to try and fail a preferred agent before the plan covers the requested drug. For Tresiba, this means glargine is typically required first. For Farxiga in type 2 diabetes, metformin step therapy is standard. The 2022 ADA-EASD consensus report states: "For patients with type 2 diabetes and established CVD, HF, or CKD, an SGLT2 inhibitor or GLP-1 RA with proven CV benefit should be used regardless of HbA1c or background metformin use" [5]. This guidance has helped prescribers override step therapy denials when the cardiac or renal indication applies.

Telehealth and Mail-Order Access

Both drugs are available through 90-day mail-order pharmacy programs, which typically reduce the per-unit cost by 10% to 15%. Telehealth prescribers can prescribe both drugs in all 50 states. Tresiba requires an accompanying sharps disposal plan and patient training on injection technique. Dapagliflozin requires counseling on euglycemic DKA risk, particularly around surgery, fasting, or severe illness [14].

Combination Therapy: Using Both Together

Why Combination Is Common

As type 2 diabetes progresses, beta-cell function declines and basal insulin becomes necessary for many patients. Adding dapagliflozin to an existing insulin regimen is FDA-approved and reduces the required insulin dose by an average of 10% to 20%, which attenuates insulin-related weight gain and hypoglycemia [10]. The 2023 ADA Standards of Care list SGLT2 inhibitor plus basal insulin as a recognized combination in the glucose-lowering treatment algorithm [5].

Titration Considerations When Combining

When initiating dapagliflozin in a patient already on insulin degludec, the prescriber should consider reducing the Tresiba dose by 10% to 20% at initiation to offset the additive glucose-lowering effect and reduce hypoglycemia risk. The FDA prescribing information for dapagliflozin includes this recommendation explicitly [2]. Monitoring should include weekly fasting glucose checks for the first 4 weeks of combination use.

Clinical Decision Framework: Which Drug for Which Patient?

The choice between dapagliflozin and insulin degludec is rarely a binary one, but the following scenarios illustrate when one agent is prioritized.

Use Farxiga first (or add to existing regimen) when: the patient has type 2 diabetes with HFrEF, HFpEF, or CKD with albuminuria (eGFR above <25 for glycemic indication); when avoiding weight gain or hypoglycemia matters; or when an oral agent is strongly preferred.

Use Tresiba first (or switch to it) when: fasting hyperglycemia is uncontrolled despite oral/non-insulin therapy; the patient has type 1 diabetes; frequent nocturnal hypoglycemia on glargine is a problem; or insulin is medically necessary and the flat pharmacokinetic profile of degludec offers clinical advantage over earlier basal insulins.

Use both together when: type 2 diabetes has progressed past the point where oral agents alone achieve target HbA1c, and the patient also has cardiovascular or renal comorbidities that warrant SGLT2 inhibitor therapy on its own evidence base.

Guideline Positions

The 2023 ADA Standards of Medical Care in Diabetes (Standards of Care) assign SGLT2 inhibitors a Grade A recommendation for patients with type 2 diabetes and established atherosclerotic CVD, heart failure, or CKD based on outcomes data [5]. The European Society of Cardiology 2023 guidelines on cardiovascular disease and diabetes recommend SGLT2 inhibitors as first-line add-on therapy in these high-risk groups, independent of glucose control [20].

Basal insulin, including insulin degludec, receives Grade A recommendation for patients with type 2 diabetes not at glycemic target on non-insulin agents. The ADA does not recommend one basal insulin brand over another for all patients, but notes that insulin degludec and glargine U-300 have demonstrated lower hypoglycemia rates than glargine U-100 in head-to-head trials, making them preferred in patients with hypoglycemia risk [5].

The DEVOTE principal investigator, Dr. John Buse, stated in commentary accompanying the trial publication: "The reduction in nocturnal hypoglycemia with degludec versus glargine is clinically meaningful and should inform insulin selection in patients with a history of hypoglycemia unawareness or recurrent overnight events" [8].